

***CURRICULUM VITAE***  
**MURRAY B. RESNICK, M.D., Ph.D.**

**Business Address:** Pathologist in Chief  
Department of Pathology and Laboratory Medicine  
Rhode Island Hospital  
593 Eddy Street, APC 12-106  
Providence, RI 02903

**Business telephone:** (401) 444-5011  
**Business fax:** (401) 444-8514  
**Electronic Mail:** [MResnick@lifespan.org](mailto:MResnick@lifespan.org)

**EDUCATION**

10/1980-10/198 University: Hadassah Medical School, Hebrew University,  
Jerusalem, BSc.  
10/1983-04/1989 Professional: Hadassah Medical School, M.D.  
10/1984-01/1989 Graduate: Hadassah Medical School, Ph.D.

**POSTGRADUATE TRAINING**

**Residency:**

7/1993-7/1994 Chief Resident in Surgical Pathology, Brigham and Women's Hospital,  
Harvard Medical School, Boston, MA  
7/1990-7/1994 Resident in Surgical Pathology, Brigham and Women's Hospital, Harvard  
Medical School, Boston, MA  
4/1989-4/1990 Intern, Hadassah Hospital

**Fellowship:**

7/1994-7/1995 Clinical Fellow, Pediatric Pathology, Children's Hospital, Boston, MA  
7/1992-7/1994 Clinical and Research Fellow, Gastrointestinal Pathology, Brigham and  
Women's Hospital, Harvard Medical School, Boston, MA  
7/1992-7/1993 Research Fellow, Infectious Disease, Beth Israel Hospital, Harvard  
Medical School, Boston, MA

**ACADEMIC/PROFESSIONAL HONORS**

2018-2020 Top Doctors Rhode Island Monthly  
2015 Masters of Arts ad eunem, Brown University, Providence, RI  
2012 Ronald DeLellis Mentoring Award, Department of Pathology and Laboratory  
Medicine, The Warren Alpert Medical School of Brown University  
2009-2010 Certificate of Recognition, Exemplary Teaching, The Warren Alpert Medical  
School of Brown University  
2008-2009 Dean's Teaching Excellence Award, The Warren Alpert Medical School of  
Brown University  
2005-2006 Dean's Teaching Excellence Award, The Warren Alpert Medical School of  
Brown University  
2004-2005 Dean's Teaching Excellence Award, The Warren Alpert Medical School of  
Brown University  
2007-present Listed in Best Doctors in America

## **ACADEMIC/PROFESSIONAL HONORS(continued)**

1985 Fulver Foundation Scholarship for excellence in studies  
1984-1987 Foulkes Foundation Scholarship for excellence in studies

## **PROFESSIONAL LICENSE & BOARD CERTIFICATION**

Rhode Island MD #10872  
Massachusetts MD #77782  
1993 American Board of Pathology

## **CURRENT POSITION**

01/2020-6/2022 Chief of Pathology and VP, PathAI, Boston, MA

## **ACADEMIC APPOINTMENTS**

2020-present Adjunct Professor of Pathology, The Warren Alpert Medical School of Brown University, Providence, RI  
2018-2019 Vice Chair of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI  
2005-2019 Professor of Pathology, The Warren Alpert Medical School of Brown University, Providence, RI  
2002-2005 Associate Professor of Pathology, The Warren Alpert Medical School of Brown University, Providence, RI  
1997-2002 Senior Lecturer Basic Sciences, Technion Medical School, Haifa, Israel  
1990-1995 Clinical and Research Fellow, Harvard Medical School, Boston, MA

## **HOSPITAL APPOINTMENTS**

07/2012-01/2020 Vice Chief of Pathology and Director of Anatomical Pathology, Rhode Island Hospital and The Miriam Hospital, Providence, RI  
07/2010-07/2012 Interim Chief of Pathology, Rhode Island Hospital and The Miriam Hospital, Providence, RI  
07/2003-07/2010 Director of Surgical Pathology, Rhode Island Hospital and The Miriam Hospital, Providence, RI  
05/2002-01/2020 Director of Gastrointestinal Pathology, Rhode Island Hospital and The Miriam Hospital, Providence, RI  
05/2002-1/2020 Director of Molecular Pathology Core Facility, Department of Pathology, Rhode Island Hospital  
05/2002-1/2020 Co-Director of Tissue Bank, Department of Pathology, Rhode Island Hospital  
08/1999-09/2000 Consultant Pathologist, Brigham and Women's Hospital and Childrens Hospital, Boston, MA  
01/1997-05/2002 Director, Department of Pathology, Carmel Medical Center, Haifa, Israel  
03/1996-05/2002 Director of Gastrointestinal Pathology Unit, Carmel Medical Center, Haifa, Israel  
09/1995-03/1996 Senior Pathologist, Sourasky Medical Center, Tel-Aviv, Israel  
07/1994-07/1995 Consultant Cytopathologist, Brigham and Women's Hospital, Boston

## **OTHER APPOINTMENTS**

2017-2019 Advisory Board, PathAI  
2010-2012 Medical Advisory Board, Diagnostics Inc, West Chester, PA  
2001-2004 Chief Medical Adviser, Proteologics Ltd, Rehovot, Israel  
2001-2002 Israeli Board for Pathology Specialty Examinations  
1998-2002 National Committee Israel Society of Pathologists  
1998-2002 Treasurer, Israeli Society for the Promotion of Research in Medicine  
1996-2000 Senior Consultant Pathologist, Patholab, Nes Ziona, Israel

## **NATIONAL COMMITTEES**

2021 Chair Search Committee Laboratory Investigation Editor-in-Chief  
2019 Search Committee, Editor in Chief, Modern Pathology, USCAP  
2015-2019 Council member, Association of Directors of Surgical and Anatomical Pathology, ADASP  
2012-2019 Chair, Publications Committee for the United States and Canadian Academy of Pathology  
2010-2019 Publications Committee for the United States and Canadian Academy of Pathology  
2009-2019 Membership Committee Arthur Purdy Stout Society  
2008-2011 United States and Canadian Academy of Pathology, Abstract Review Committee for Techniques in Pathology  
2004-2007 Gastrointestinal Liaison Committee, Radiation Therapy Oncology Group (RTOG)  
2004-2007 Education Committee Roger Haggitt Gastrointestinal Pathology Society, United States and Canadian Academy of Pathology

## **HOSPITAL COMMITTEES**

2010-2012 Medical Executive Committee, The Miriam Hospital  
Cancer Committee, The Miriam Hospital  
2005-2019 Quality Assurance, Department of Pathology, Rhode Island Hospital  
2003-2019 Internal Executive Committee, Center for Cancer Research Development (COBRE), Rhode Island Hospital Gastrointestinal Cancer Genetics Committee

## **UNIVERSITY COMMITTEES**

2012-2019 Committee on Medical Faculty Appointments  
Residency Program Evaluation Committee  
Residency Selection Committee, Department of Pathology  
Departmental Promotions Committee, Department of Pathology  
Translational Research Subcommittee  
BrUOG Scientific Advisory Board

## **BROWN UNIVERSITY and HOSPITAL SEARCH COMMITTEES**

2004-2019 Several departmental surgical pathology positions as Chair  
2012 Senior researcher, Department of Pathology, The Warren Alpert Medical School of Brown University

## **BROWN UNIVERSITY and HOSPITAL SEARCH COMMITTEES(continued)**

2018 Chair, Senior Cancer Biologist, Department of Pathology, The Warren Alpert Medical School of Brown University  
2018 Chair, Senior Cancer Biologist, Department of Oncology, The Warren Alpert Medical School of Brown University  
2019 Director of Pediatric Surgery, Hasbro Children's Hospital  
2019 Director of Hepatobiliary Surgery, Rhode Island Hospital

### **MEMBERSHIP IN SOCIETIES**

American Association of Directors of Surgical Pathologists  
Association of Pathology Chairs  
American Gastroenterological Association  
American Society of Clinical Pathology  
United States and Canadian Academy of Pathology  
Roger Haggitt Gastrointestinal Pathology Society  
Arthur Purdy Stout Society of Pathology  
American Association for Cancer Research  
College of American Pathology

### **BIOPHARMACEUTICAL CONSULTATION EXPERIENCE**

Diagnocure Inc, West Chester, PA  
XTL Biopharmaceuticals, Nes Ziona, Israel  
BioView, Nes Ziona, Israel  
Collgard Biopharmaceuticals, Tel-Aviv, Israel  
Ultracure Ltd, Tirat Hacarmel, Israel  
Proteologics, Rehovot, Israel  
Polyheal, Nesher, Israel

### **SCIENTIFIC AND MEDICAL JOURNAL EDITORIAL BOARD**

2010-present	Human Pathology
2010-present	Modern Pathology
2010-present	Applied Immunohistochemistry & Molecular Morphology
2018-2019	Cancer Biology and Therapy
2018-present	Laboratory Investigation, Associate Editor
2016-2018	Laboratory Investigation

### **SCIENTIFIC AND MEDICAL JOURNAL AD HOC REVIEWER**

American Journal of Gastroenterology  
Archives of Pathology and Laboratory Medicine  
BMC Cancer  
British Journal of Cancer  
Cancer Detection and Prevention  
Carcinogenesis  
Clinical Cancer Research  
Digestive Diseases and Science

### **SCIENTIFIC AND MEDICAL JOURNAL AD HOC REVIEWER(continued)**

European Journal of Cancer

Gut  
International Journal of Cancer  
Journal of Biomedical Imaging  
Journal of Clinical Oncology  
Journal of Hepatology  
Journal of Histochemistry and Cytochemistry  
Neoplasia  
PloS Medicine Online  
Virchows Archives

### **SCIENTIFIC GRANT REVIEWER**

Cancer Research, Translational Research in Clinical Trials, United Kingdom  
NMRC, Singapore  
Genesis Oncology Trust, New Zealand  
Department of Veterans Affairs Cooperative Studies Program

### **PUBLICATIONS**

1. **Resnick M**, Schuldiner S, Bercovier H. Bacterial membrane potential analyzed by spectrofluorocytometry. *Curr Microbiol* 1985; 12:183-186.
2. Ginsberg I, Mor N, **Resnick M**, Bercovier H. Polycationic agent facilitates endocytosis of microorganisms by amoebae. *Eur J Cell Biol* 1986; 41:130-133.
3. **Resnick M**, Bercovier H, Mor N, Levy L. Unforeseen death of *Mycobacterium lepraemurium* in infected susceptible mice. *J Infect Dis.* 1986 Feb;153(2):368-70. No abstract available. PMID: 2935583.
4. **Resnick M**, Bercovier H, Aizer F, Mor N, Levy L. Death of *Mycobacterium lepraemurium* after multiplication in CBA, BALB/c and nude mice. *Ann Inst Pasteur Microbiol.* 1987 Jan-Feb;138(1):15-9. PMID: 2955800.
5. Bercovier H, **Resnick M**, Kornitzer D, Levy L. Rapid method for testing drug susceptibility of *Mycobacterium* spp. and gram-positive bacteria using rhodamine 123 and fluorescein diacetate. *Microbiol Methods* 1987; 7:139-142.
6. **Resnick M**, Roguel N, Bercovier H, Enk C, Frankenburg S, Kedar E. Lysis of murine macrophages infected with intracellular pathogens by interleukin 2-activated killer (LAK) cells in vitro. *Cell Immunol.* 1988 Apr 15;113(1):214-9. PMID: 3259166.
7. Mor N, **Resnick M**, Silbaq F, Bercovier H, Levy L. Reduction of tellurite and deesterification of fluorescein diacetate are not well correlated with the viability of mycobacteria. *Ann Inst Pasteur Microbiol.* 1988 May-Jun;139(3):279-88. PMID: 3179056.

### **PUBLICATIONS(continued)**

8. **Resnick M**, Ben-Ishay Z, Mor N, Levy L, Bercovier H. Hemophagocytosis and other haematological aspects of *Mycobacterium lepraemurium* disease of mice. *J Comp Pathol*. 1988 Jul;99(1):65-75. PMID: 3062053.
9. **Resnick M**, Fibach E, Lebastard M, Levy L, Bercovier H. Response of the murine hematopoietic system to chronic infection with *Mycobacterium lepraemurium*. *Infect Immun*. 1988 Dec;56(12):3145-51. PMID: 3053453.
10. **Resnick M**, Roguel-Resnick N, Bercovier H, Levy L, Toledo J, Zipori D. Detection of interleukin-3 in the serum of mice infected with *Mycobacterium lepraemurium*. *J Infect Dis*. 1990 Nov;162(5):1202-4. PMID: 2230246.
11. Costa JJ, Matossian K, **Resnick MB**, Beil WJ, Wong DT, Gordon JR, Dvorak AM, Weller PF, Galli SJ. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. *J Clin Invest*. 1993 Jun;91(6):2673-84. PMID: 8514874.
12. **Resnick MB**, Colgan SP, Patapoff TW, Mrsny RJ, Awtrey CS, Delp-Archer C, Weller PF, Madara JL. Activated eosinophils evoke chloride secretion in model intestinal epithelia via regulated release of 5'-AMP. *J Immunol*. 1993 Nov 15;151(10):5716-23. PMID: 8228257.
13. Colgan SP, **Resnick MB**, Parkos CA, Delp-Archer C, McGuirk D, Bacarra AE, Weller PF, Madara JL. IL-4 directly modulates function of a model human intestinal epithelium. *J Immunol*. 1994 Sep 1;153(5):2122-9. PMID: 7914217.
14. Lim KG, Wan HC, **Resnick M**, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF. Human eosinophils release the lymphocyte and eosinophil active cytokines, RANTES and lymphocyte chemoattractant factor. *Int Arch Allergy Immunol*. 1995 May-Jun;107(1-3):342. No abstract available. PMID: 7542086.
15. **Resnick MB**, Colgan SP, Parkos CA, Delp-Archer C, McGuirk D, Weller PF, Madara JL. Human eosinophils migrate across an intestinal epithelium in response to platelet-activating factor. *Gastroenterology*. 1995 Feb;108(2):409-16. PMID: 7835581.
16. **Resnick MB**, Kozakewich HP, Perez-Atayde AR. Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. *Am J Surg Pathol*. 1995 Oct;19(10):1181-90. PMID: 7573676.
17. **Resnick MB**, Gallinger S, Wang HH, Odze RD. Growth factor expression and proliferation kinetics in periampullary neoplasms in familial adenomatous polyposis. *Cancer*. 1995 Jul 15;76(2):187-94. PMID: 8625090.
18. **Resnick M**, Lester S, Tate JE, Sheets EE, Sparks C, Crum CP. Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. *Hum Pathol*. 1996 Mar;27(3):234-9. PMID: 8600036.

**PUBLICATIONS(continued)**

19. Tate JE, **Resnick M**, Sheets EE, Crum CP. Absence of papillomavirus DNA in normal tissue adjacent to most cervical intraepithelial neoplasms. *Obstet Gynecol.* 1996 Aug;88(2):257-60. PMID: 8692512.
20. Lim KG, Wan HC, Bozza PT, **Resnick MB**, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF. Human eosinophils elaborate the lymphocyte chemoattractants: IL-16 (lymphocyte chemoattractant factor) and RANTES. *J Immunol.* 1996 Apr 1;156(7):2566-70. PMID: 8786320.
21. Turner JR, Odze RD, Crum CP, **Resnick MB**. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. *Hum Pathol.* 1997 Jun;28(6):740-4. PMID: 9191010.
22. **Resnick MB**, Schacter P, Finkelstein Y, Kellner Y, Cohen O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. *Mod Pathol.* 1998 Aug;11(8):735-9. PMID: 9720501.
23. Oren R, **Resnick MB**, Brill S, Dotan I, Zaidel L, Lifshits-Mercer B, Halpern Z. Thyroxine accelerates proliferation of injured liver cells. *J Hepatol.* 1998 Oct;29(4):634-7. PMID: 9824273.
24. Rahat MA, Lahat N, Gazawi H, **Resnick MB**, Sova Y, Ben-Ari G, Cohen M, Stein A. Telomerase activity in patients with transitional cell carcinoma: a preliminary study. *Cancer.* 1999 Feb 15;85(4):919-24. PMID: 10091771.
25. **Resnick MB**, Finkelstein Y, Weissler A, Levy J, Yakirevitch E. Assessment and diagnostic utility of the cytotoxic T-lymphocyte phenotype using the specific markers granzyme-B and TIA-1 in esophageal mucosal biopsies. *Hum Pathol.* 1999 Apr;30(4):397-402. PMID: 10208460.
26. Avivi A, **Resnick MB**, Nevo E, Joel A, Levy AP. Adaptive hypoxic tolerance in subterranean mole rats *Spalax ehrenbergi*: the role of vascular endothelial growth factor. *FEBS Lett.* 1999 Jun 11;452(3):133-40. PMID: 10386577.
27. Korem S, **Resnick MB**, Kraiem Z. Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. *J Clin Endocrinol Metab.* 1999 Sep;84(9):3322-7. PMID: 10487706.
28. Jakobovitz-Picard O, Olchovsky D, Nativ O, **Resnick MB**, Rechavi G, Karasik A, Friedman E. A germline mutation in the von Hippel-Lindau disease gene (L178Q) detected by denaturing gradient gel electrophoresis in a large Jewish-Yemenite family. *Hum Mutat.* 1999 Nov;14(5):448. No abstract available. PMID:10533077.
29. Yakirevitch Y, Izhak OB, Rennert G, Kovacs ZG, **Resnick MB**. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. *Mod Pathol.* 1999 Nov;12(11):1050-6. PMID: 10574602.

**PUBLICATIONS(continued)**

30. Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, **Resnick MB**, Lifzchiz-Mercerl B, Lew S, Iscovich J. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. *Am J Hum Genet.* 1999 Dec;65(6):1800-2. No abstract available. PMID: 10577940.
31. Shupak A, Arieli R, Rosenhause G, **Resnick MB**, Arieli Y, Adir Y. The effect of low-frequency ultrasound on immersed pig lungs. *Ultrasound Med Biol.* 1999 Nov;25(9):1439-43. PMID: 10626632.
32. Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, **Resnick M**, Stein A. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. *Eur Urol.* 2000 May;37(5):601-4. PMID: 10765100.
33. Yakirevitch E, Maroun L, Cohen O, Izhak OB, Rennert G, **Resnick MB**. Apoptosis, proliferation and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast. *J Pathol.* 2000 Oct;192(2):166-73. PMID: 11004692.
34. Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, **Resnick MB**. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. *Clin Cancer Res.* 2001 Mar;7(3):533-7. PMID: 11297244.
35. Cohen T, Gluzman-Poltorak Z, Brodzky A, Meytal V, Sabo E, Misselevich I, Hassoun M, Boss JH, **Resnick M**, Shneyvas D, Eldar S, Neufeld G. Neuroendocrine cells along the digestive tract express neuropilin-2. *Biochem Biophys Res Commun.* 2001 Jun 8;284(2):395-403. PMID: 11394892.
36. Yakirevitch E, Lefel O, Sova Y, Stein A, Cohen O, Izhak OB, **Resnick MB**. Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. *J Pathol.* 2002 Jan;196(1):67-75. PMID: 11748644.
37. Cohen-Kerem R, Lahat N, Elmalah I, Greenberg E, **Resnick MB**, Doweck I, Rahat MA. Detection of cytokeratins in normal and malignant laryngeal epithelia by means of reverse transcriptase-polymerase chain reaction. *Ann Otol Rhinol Laryngol.* 2002 Feb;111(2):149-54. PMID:11860067.
38. Yakirevich E, Yanai O, Sova Y, Sabo E, Stein A, Hiss J, **Resnick MB**. Cytotoxic phenotype of intraepithelial lymphocytes in normal and cryptorchid human testicular excurrent ducts. *Hum Reprod.* 2002 Feb;17(2):275-83. PMID: 11821263.
39. Korem S, Kraiem Z, Shiloni E, Yehezkel O, Sadeh O, **Resnick MB**. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. *Isr Med Assoc J.* 2002 Apr;4(4):247-51. PMID: 12001695.
40. Cohen T, Herzog Y, Brodzky A, Greenson JK, Eldar S, Gluzman-Poltorak Z, Neufeld G, **Resnick MB**. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. *J Pathol.* 2002 Sep;198(1):77-82. PMID: 12210066.

**PUBLICATIONS(continued)**



41. **Resnick MB**, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. *Int J Cancer*. 2002 Sep 10;101(2):190-5. PMID: 12209997.
42. Yakirevich E, Sabo E, Dirnfeld M, Sova Y, Spagnoli GC, **Resnick MB**. Morphometrical quantification of spermatogonial germ cells with the 57B anti-MAGE-A4 antibody in the evaluation of testicular biopsies for azoospermia. *Appl Immunohistochem Mol Morphol*. 2003 Mar;11(1):37-44. PMID: 12610355.
43. Sabo E, Gibrat M, Sova Y, Stein A, **Resnick MB**. Validation of the novel indices of nuclear pleomorphism, polarity and spatial distribution in the grading of urothelial carcinoma. *Anal Quant Cytol Histol*. 2003 Feb;25(1):53-62. PMID: 12630083.
44. Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvily Y, Gan N, Kessler O, Cohen T, **Resnick M**, Neeman M, Neufeld G. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. *Cancer Res* 2003 Apr 1;63(7):1657-66. PMID: 12670920.
45. Sukhotnik I, Krausz MM, Sabo E, **Resnick M**, Hirsh M, Mannheim D, Shiloni E. Endotoxemia inhibits intestinal adaptation in a rat model of short bowel syndrome. *Shock* 2003 Jan;19(1):66-70. PMID: 12558147.
46. Roguin A, Avivi A, Nitecki S, Rubinstein I, Levy NS, Abassi ZA, **Resnick MB**, Lache O, Melamed-Frank M, Joel A, Hoffman A, Nevo E, Levy AP. Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat *Spalax ehrenbergi* VEGF. *Proc Natl Acad Sci U S A*. 2003 Apr 15;100(8):4644-8. Epub 2003 Apr 2. PMID: 12672967.
47. Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, **Resnick MB**, Trougouboff P, Tomsho LD, Kim E, Low M, Almog R, Rennert G, Gruber SB. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. *Am J Surg Pathol*. 2003 May;27(5):563-70. PMID: 12717242.
48. Zeitlin L, **Resnick MB**, Konikoff F, Schuppan D, Bujanover Y, Lerner A, Belson A, Lifschitz B, Reif S. Divergent patterns of extracellular matrix protein expression in neonatal versus adult liver fibrosis. *Pediatr Pathol Mol Med*. 2003 Jul-Aug;22(4):349-62. PMID: 14692230.
49. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, **Resnick MB**. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. *Clin Cancer Res*. 2003 Dec 15;9(17):6453-60. PMID: 14695148.
50. **Resnick MB**, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. *Clin Cancer Res*. 2004 May 1;10(9):3069-75. PMID: 15131045.

**PUBLICATIONS(continued)**

51. Horimoto M, **Resnick MB**, Konkin TA, Routhier J, Wands JR, Baffy G. Expression of uncoupling protein-2 in human colon cancer. *Clin Cancer Res.* 2004 Sep 15;10(18 Pt 1):6203-7. PMID: 15448008.
52. Kondratiev S, Sabo E, Yakirevich E, Lavie O, **Resnick MB**. Intratumoral CD8<sup>+</sup> T lymphocytes as a prognostic factor of survival in human endometrial carcinoma. *Clin Cancer Res.* 2004 Jul 1;10(13):4450-6. PMID: 15240536.
53. **Resnick MB**, Konkin T, Routhier J, Sabo E, Pricolo VE. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. *Mod Pathol.* 2005 Apr;18(4):511-8. PMID: 15475928.
54. Rosenbaum-Dekel Y, Fuchs A, Yakirevich Y, Azriel A, Mazareb S, **Resnick MB**, Levi BZ. Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis. *Biochem Biophys Res Commun.* 2005 Jun 24;332(1):271-8. PMID: 15896327.
55. **Resnick MB**, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. *Hum Pathol.* 2005 Aug;36(8):886-92. PMID: 16112005.
56. Kim SS, Meitner P, Konkin TA, Cho YS, **Resnick MB**, Moss SF. Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis. *Mod Pathol.* 2006 Jan;19(1):49-58. PMID: 16118628.
57. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, **Resnick MB**. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. *Gynecol Oncol.* 2006 Jan;100(1):152-9. Epub 2005 Sep 29. PMID: 16198399.
58. Derdák Z, Fülöp P, Sabo E, Tavares R, Berthiaume EP, **Resnick MB**, Paragh G, Wands JR, Baffy G. Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. *Carcinogenesis.* 2006 May;27(5):956-61. Epub 2006 Jan 9. PMID: 16401637.
59. **Resnick MB**, Sabo E, Meitner PA, Kim SS, Cho Y, Kim H, Tavares R, Moss S. Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo. *Gut.* 2006 Dec;55(12):1717-24. Epub 2006 Apr 26. PMID: 16641130.
60. Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X, Reddy SP, **Resnick MB**, Kalvakolanu DV. A proteomic analysis reveals loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. *Oncogene.* 2006 Nov 16;25(54):7138-47. Epub 2006 May 29. PMID: 16732315.
61. Fülöp P, Derdák Z, Sheets A, Sabo E, Berthiaume EP, **Resnick MB**, Wands JR, Paragh G, Baffy G. Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. *Hepatology.* 2006 Sep;44(3):592-601. PMID: 16941708.

**PUBLICATIONS(continued)**

62. Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, Hovanesian V, Monfils PR, **Resnick M**, Moss SF, Ramratnam B. Engineering mucosal RNA interference in vivo. *Mol Ther*. 2006 Sep;14(3):336-42. Epub 2006 Jun 12. PMID: 16766229.
63. Sabo E, Beck AH, Montgomery EA, Bhattacharya B, Meitner P, Wang JY, **Resnick MB**. Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's Esophagus Lab Invest. 2006 Dec;86(12):1261-71. Epub 2006 Oct 30. PMID: 17075582.
64. Filardo EJ, Graeber CT, Quinn JA, **Resnick MB**, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a seven-membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathological determinants of tumor progression. *Clin Cancer Res*. 2006 Nov 1;12(21):6359-66. PMID: 17085646.
65. Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, Simao L, Wands JR, **Resnick MB**. Prognostic value of humbug gene overexpression in stage II colon cancer. *Hum Pathol*. 2007 Jan;38(1):17-25. Epub 2006 Oct 3. PMID: 17020779.
66. Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E, Liu Q, Hsieh CC, Bhat G, Frackelton AR Jr, Hafer LJ. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. *Clin Cancer Res*. 2007 Oct 1;13(19):5798-804. PMID: 17908971.
67. Bhattacharya B, Carlsten J, Sabo E, Kethu S, Meitner P, Tavares R, Jakate S, Mangray S, Aswad B, **Resnick MB**. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. *Hum Pathol*. 2007 Dec;38(12):1744-53. Epub 2007 Sep 27. PMID: 17900656.
68. Yakirevich E, Jackson CL, Meitner PA, MacKenzie D, Tavares R, Robinson-Bostom L, DeLellis RA, **Resnick MB**. Analysis of T-cell clonality using laser capture microdissection and high-resolution microcapillary electrophoresis. *J Mol Diagn*. 2007 Sep;9(4):490-7. Epub 2007 Jul 9. PMID: 17620388.
69. Wolff JH, Rubin A, Potter JD, Lattimore W, **Resnick MB**, Murphy BL, Moss SF. Clinical significance of colonoscopic findings associated with colonic thickening on computed tomography: is colonoscopy warranted when thickening is detected? *J Clin Gastroenterol*. 2008 May-Jun;42(5):472-5. doi: 10.1097/MCG.0b013e31804c7065. PMID: 18344892.
70. Yakirevich E, Morris DJ, Tavares R, Meitner PA, Lechpammer M, Noble L, de Rodriguez AF, Gomez-Sanchez CE, Wang LJ, Sabo E, DeLellis RA, **Resnick MB**. Mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study. *Am J Surg Pathol*. 2008 Jun;32(6):874-83. doi: 10.1097/PAS.0b013e31815f2362. PMID: 18408592.
71. Chatterjee D, Sabo E, Tavares R, **Resnick MB**. Inverse association between Raf Kinase Inhibitory Protein and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. *Clin Cancer Res*. 2008 May 15;14(10):2994-3001. doi: 10.1158/1078-0432.CCR-07-4496. PMID: 18483365.

**PUBLICATIONS(continued)**

72. Safran H, Miner T, **Resnick M**, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N, Kennedy T. apatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. *Am J Clin Oncol*. 2008 Apr;31(2):140-4. doi: 10.1097/COC.0b013e318145b9a5. PMID: 18391597.
73. Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. *Mod Pathol*. 2008 Nov;21(11):1320-9. doi: 10.1038/modpathol.2008.116. Epub 2008 Jun 27. Erratum in: *Mod Pathol*. 2009 Feb;22(2):321. PMID: 18587324.
74. Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FE, Gao J, Meitner PA, Tavares R, **Resnick MB**. Decreased expression of the gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. *Clin Cancer Res*. 2008 Jul 1;14(13):4161-7. doi: 10.1158/1078-0432.CCR-07-4381. PMID: 18593995.
75. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, **Resnick MB**. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. *Clin Cancer Res*. 2008 Oct 15;14(20):6440-8. doi: 10.1158/1078-0432.CCR-08-0302. PMID: 18927283. Lockhart AC, Harris E, LaFleur BJ, Merchant NB, Washington MK, **Resnick MB**, Yeatman TJ, Lee W. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. *Clin Exp Gastroenterol*. 2008;1:1-7. Epub 2008 Nov 2. PMID: 21677819.
76. Winn B, Tavares R, Fanion J, Noble L, Gao J, Sabo E, **Resnick MB**. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. *Hum Pathol*. 2009 Mar;40(3):398-404. doi: 10.1016/j.humpath.2008.08.014. Epub 2008 Nov 7. PMID: 18992917.
77. Paul E, Cronan R, Weston PJ, Boekelheide K, Sedivy JM, Lee SY, Wiest DL, **Resnick MB**, Klysik JE. Disruption of Supv3L1 damages the skin and causes sarcopenia, loss of fat, and death. *Mamm Genome*. 2009 Feb;20(2):92-108. doi: 10.1007/s00335-008-9168-z. Epub 2009 Jan 15. PMID: 19145458.
79. Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, Simao L, Wands JR, **Resnick MB**, Wang L. Prognostic value of aspartyl (asparaginy)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. *Hum Pathol*. 2009 May;40(5):639-44. doi: 10.1016/j.humpath.2008.11.001. Epub 2009 Feb 5. PMID: 19200576.
80. Wang LJ, Greaves WO, Sabo E, Noble L, Tavares R, Ng T, DeLellis RA, **Resnick MB**. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. *Appl Immunohistochem Mol Morphol*. 2009 Dec;17(6):505-11. doi: 10.1097/PAI.0b013e3181a8e809. PMID: 19620839.

## **PUBLICATIONS(continued)**

81. McGowan CE, Saha S, Chu G, **Resnick MB**, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. *South Med J*. 2009 May;102(5):493-7. doi: 10.1097/SMJ.0b013e31819e8978. PMID: 19373153.
82. Winn B, Tavares R, Matoso A, Noble L, Fanion J, Waldman SA, **Resnick MB**. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. *Hum Pathol*. 2010 Jan;41(1):123-8. doi: 10.1016/j.humpath.2009.07.009. Epub 2009 Oct 1. PMID: 19800103.
83. Matoso A, Singh K, Jacob R, Greaves WO, Tavares R, Noble L, **Resnick MB**, DeLellis RA, Wang LJ. Comparison of thyroid transcription factor-1 expression by two monoclonal antibodies in pulmonary and nonpulmonary primary tumors. *Appl Immunohistochem Mol Morphol*. 2010 Mar;18(2):142-9. doi: 10.1097/PAI.0b013e3181bdf4e7. PMID: 19887917.
84. Hong J, Behar J, Wands J, **Resnick M**, Wang LJ, DeLellis RA, Lambeth D, Souza RF, Spechler SJ, Cao W. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. *Gut*. 2010 Feb;59(2):170-80. doi: 10.1136/gut.2009.188375. Epub 2009 Nov 18. PMID: 19926617.
85. Hong J, Behar J, Wands J, **Resnick M**, Wang LJ, DeLellis RA, Lambeth D, Cao W. Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase Cgamma2 and NADPH oxidase NOX5-S. *Cancer Res*. 2010 Feb 1;70(3):1247-55. doi: 10.1158/0008-5472.CAN-09-2774. Epub 2010 Jan 19. PMID: 20086178.
86. Charpentier KP, Wolf F, Noble L, Winn B, **Resnick M**, Dupuy DE. Irreversible electroporation of the pancreas in swine: a pilot study. *HPB (Oxford)*. 2010 Jun;12(5):348-51. doi: 10.1111/j.1477-2574.2010.00174.x. PMID: 20590911.
87. Hong J, **Resnick M**, Behar J, Wang LJ, Wands J, DeLellis RA, Souza RF, Spechler SJ, Cao W. Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. *Am J Physiol Gastrointest Liver Physiol*. 2010 Sep;299(3):G697-706. doi: 10.1152/ajpgi.00186.2010. Epub 2010 Jun 24. PMID: 20576920.
88. Pricolo VE, Abodeely A, **Resnick M**. Distal margins in radical resections for rectal cancer after chemoradiation therapy: how short is long enough? *Dig Surg*. 2010 Aug;27(3):185-9. doi: 10.1159/000274464. Epub 2010 Jun 22. PMID: 20571264.
89. Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, **Resnick MB**, Houseman EA, Kelsey KT, Marsit CJ. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. *Int J Cancer*. 2010 Dec 15;127(12):2859-69. doi: 10.1002/ijc.25285. PMID: 21351265.
90. Gee GV, Stanifer ML, Christensen BC, Atwood WJ, Ugolini D, Bonassi S, **Resnick MB**, Nelson HH, Marsit CJ, Kelsey KT. SV40 associated miRNAs are not detectable in mesotheliomas. *Br J Cancer*. 2010 Sep 7;103(6):885-8. doi: 10.1038/sj.bjc.6605848. Epub 2010 Aug 17. PMID: 20717113.

## **PUBLICATIONS(continued)**

91. Yakirevich E, Matoso A, Sabo E, Wang LJ, Tavares R, Meitner P, Morris DJ, Pareek G, Delellis RA, **Resnick MB**. Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study. *Hum Pathol*. 2011 Nov;42(11):1684-92. doi: 10.1016/j.humpath.2011.01.014. Epub 2011 Apr 29. PMID: 21531004.
92. Sargent DJ, Resnick MB, Meyers MO, Goldar-Najafi A, Clancy T, Gill S, Siemons GO, Shi Q, Bot BM, Wu TT, Beaudry G, Haince JF, Fradet Y. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. *Ann Surg Oncol*. 2011 Nov;1(12):3261-70. doi: 10.1245/s10434-011-1731-2. Epub 2011 May 1. PMID: 21533822.
93. Hong J, **Resnick M**, Behar J, Wands J, Delellis RA, Cao W. Role of RAC1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells. *Am J Physiol Cell Physiol*. 2011 Aug;301(2):C413-20. doi: 10.1152/ajpcell.00027.2011. Epub 2011 Apr 27. PMID: 21525435.
94. Zhou X, Li D. **Resnick MB**, Behar J, Wands J, Cao W. Signaling in H<sub>2</sub>O<sub>2</sub>-induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells. *J Pharmacol Exp Ther*. 2011 Oct;339(1):218-27. doi: 10.1124/jpet.111.182352. Epub 2011 Jul 12. PMID: 21750116.
95. O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, **Resnick MB**, Neilson EG, Zeisberg M, Kalluri R. VEGF-A and tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. *Proc Natl Acad Sci U S A*. 2011 Sep 20;108(38):16002-7. doi: 10.1073/pnas.1109493108. Epub 2011 Sep 12. PMID: 21911392.
96. Wang LJ, Matoso A, Sciandra KT, Yakirevich E, Sabo E, Zhang Y, Meitner PA, Tavares R, Noble L, Pareek G, DeLellis RA, **Resnick MB**. Expression of S100A4 in renal epithelial neoplasms. *Appl Immunohistochem Mol Morphol*. 2012 Jan;20(1):71-6. doi: 10.1097/PAI.0b013e31821fc8b7. PMID: 21691200.
97. Wen S, So Y, Singh K, Slingerland JM, **Resnick MB**, Zhang S, Ruiz V, Moss SF. Promotion of cytoplasmic mislocalization of p27 by *Helicobacter pylori* in gastric cancer. *Oncogene*. 2012 Apr 5;31(14):1771-80. doi: 10.1038/onc.2011.362. Epub 2011 Aug 15. PMID: 21841827.
98. Grand DJ, Kampalath V, Harris A, Patel A, **Resnick MB**, Machan J, Beland M, Chen WT, Shah SA. MR enterography correlates highly with colonoscopy and histology for both distal ileal and colonic Crohn's disease in 310 patients. *Eur J Radiol*. 2012 May;81(5):e763-9. doi: 10.1016/j.ejrad.2012.02.011. Epub 2012 Mar 23. PMID: 22445795.
99. Lu S, Mukkada VA, Mangray S, Cleveland K, Shillingford N, Schorl C, Brodsky AS, **Resnick MB**. MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post treatment with steroids and relationship with mRNA targets. *PLoS One*. 2012;7(7):e40676. doi: 10.1371/journal.pone.0040676. Epub 2012 Jul 16. PMID: 22815788.

## **PUBLICATIONS(continued)**

100. Cao W, Tian W, Hong J, Li D, Tavares R, Noble L, Moss SF, **Resnick MB**. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. *Am J Physiol Gastrointest Liver Physiol*. 2013 Feb 15;304(4):G322-7. doi: 10.1152/ajpgi.00263.2012. Epub 2012 Dec 13. PMID: 23238937.
101. Lu S, Singh K, Mangray S, Tavares R, Noble L, **Resnick MB**, Yakirevich E. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. *Mod Pathol*. 2013 Apr;26(4):485-95. doi: 10.1038/modpathol.2012.187. Epub 2012 Dec 7. PMID:23222490.
102. Matoso A, Mukkada VA, Lu S, Monahan R, Cleveland K, Noble L, Mangray S, **Resnick MB**. Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. *Mod Pathol*. 2013 May;26(5):665-76. doi: 10.1038/modpathol.2013.41. Epub 2013 Mar 15. PMID: 23503644.
103. Zhou X, Li D, **Resnick MB**, Wands J, Cao W. NADPH oxidase NOX5-S and nuclear factor  $\kappa$ B1 mediate acid-induced microsomal prostaglandin E synthase-1 expression in Barrett's esophageal adenocarcinoma cells. *Mol Pharmacol*. 2013 May;83(5):978-90. doi: 10.1124/mol.112.083287. Epub 2013 Feb 25. PMID: 23439561.
104. Ratanaprasatporn L, Charpentier KP, **Resnick M**, Lu S, Dupuy D. Intra-operative microwave ablation of liver malignancies with tumour permittivity feedback control: a prospect ablate and resect study. *HPB (Oxford)* 2013 Dec;15(12):997-1001. doi: 10.1111/hpb.12084. Epub 2013 Mar 29. PMID: 23551845.
105. Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C, Quesenberry PJ, **Resnick MB**, Chatterjee D. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. *BMC Cancer*. 2013 Oct 8;13:463. doi: 10.1186/1471-2407-13-463. PMID: 24098947.
106. Taliano RJ, Lu S, Singh K, Mangray S, Tavares R, Noble L, **Resnick MB**, Yakirevich E. Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis. *Hum Pathol*. 2013 Dec;44(12):2743-50. doi: 10.1016/j.humphath.2013.07.021. PMID: 24262018.
107. Lu S, Herzlinger M, Cao W, Noble L, Yang D, Shapiro J, Kurtis J, LeLeiko N, Resnick M. Utility of 15(S)-HETE as a serological marker for eosinophilic esophagitis. *Sci Rep* 2018 Sep 28;8(1):14498. doi: 10.1038/s41598-018-32944-8. PMID: 30266946.
108. Ellermeier C, Vang S, Cleveland K, Durand W, **Resnick MB**, Brodsky AS. Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. *Anticancer Res*. 2014 Aug;34(8):3957-67. PMID: 25075017.
109. Snow A, Mangray S, Lu S, Clubwala R, Li J, **Resnick MB**, Yakirevich E. Expression of cadherin 17 in well-differentiated neuroendocrine tumours. *Histopathology*. 2015 Jun;66(7):1010-21. doi: 10.1111/his.12610. Epub 2015 Jan 13. PMID: 25388236.

## **PUBLICATIONS(continued)**

110. Yakirevich E, Ali SM, Mega A, McMahon C, Brodsky AS, Ross JS, Allen J, Elvin JA, Safran H, **Resnick MB**. A novel SDHA-deficient renal cell carcinoma revealed by comprehensive genomic profiling. *Am J Surg Pathol*. 2015 Jun;39(6):858-63. doi: 10.1097/PAS.0000000000000403. PMID: 25724004.
111. Yakirevich E, Magi-Galluzzi C, Grada Z, Lu S, **Resnick MB**, Mangray S. Cadherin 17 is a sensitive and specific marker of metanephric adenoma. *Am J Surg Pathol*. 2015 Apr;39(4):479-86. doi: 10.1097/PAS.0000000000000401. PMID: 25768256.
112. Yakirevich E, Henriksen KJ, Miner T, **Resnick MB**. Mucinous cystic neoplasm of the pancreas with increased IgG4+ plasma cells and histopathologic features of autoimmune pancreatitis/IgG4-related disease. *Pancreas*. 2015 May;44(4):674-6. doi: 10.1097/MPA.0000000000000296. No abstract available. PMID: 25872133.
113. Friedman K, **Resnick MB**, Safran H. Mutation profiling of clinically advanced cancers using next-generation sequencing for targeted therapy: a Lifespan experience. *R I Med J* (2013). 2015 Oct 1;98(10):16-20. PMID: 26422540.
114. Yakirevich E, **Resnick MB**, Mangray S, Wheeler M, Jackson CL, Lombardo KA, Lee J, Kim KM, Gill AJ, Wang K, Gowen K, Sun J, Miller VA, Stephens PJ, Ali SM, Ross JS, Safran H. Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. *Clin Cancer Res*. 2016 Aug 1;22(15):3831-40. doi: 10.1158/1078-0432.CCR-15-3000. Epub 2016 Mar 1. PMID: 26422540.
115. Friedman K, Brodsky AS, Lu S, Wood S, Gill AJ, Lombardo K, Yang D, **Resnick MB**. Medullary carcinoma of the colon: A distinct morphology reveals a distinctive immunoregulatory microenvironment. *Mod Pathol*. 2016 May;29(5):528-41. doi: 10.1038/modpathol.2016.54. Epub 2016 Mar 11. PMID: 26965581.
116. Brodsky AS, Xiong J, Yang D, Schorl C, Fenton MA, Graves TA, Sikov WM, **Resnick MB**, Wang Y. Identification of stromal ColX $\alpha$ 1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. *BMC Cancer*. 2016 Apr 18;16:274. doi: 10.1186/s12885-016-2302-5. PMID: 27090210.
117. Patel K, Strother RM, Ndiangui F Chumba D, Jacobson W, Dodson C, **Resnick MB**, Strate RW, Smith JW. Development of immunohistochemistry services for cancer care in western Kenya: Implications for low- and middle-income countries. *Afr J Lab Med*. 2016 May 4;5(1):187. doi: 10.4102/ajlm.v5i1.187. eCollection 2016. PMID: 28879100.
118. Wang Y, **Resnick MB**, Lu S, Hui Y, Brodsky AS, Yang D, Yakirevich E, Wang L. Collagen type III  $\alpha$ 1 is a useful diagnostic immunohistochemical marker for fibroepithelial lesions of the breast. *Hum Pathol*. 2016 Nov;57:176-181. doi: 10.1016/j.humpath.2016.07.017. Epub 2016 Aug 3. PMID: 27498063.



## **PUBLICATIONS(continued)**

119. Wang Y, Lu S, Graves T, Ouseph MM, **Resnick MB**, Yakirevich E. Can sentinel lymph node biopsy be spared in papillary carcinoma of the breast? *Clin Breast Cancer*. 2017 Apr;17(2):127-133. doi: 10.1016/j.clbc.2016.08.009. Epub 2016 Sep 8. PMID: 27692774.
120. Wood SM, Gill AJ, Brodsky AS, Lu S, Friedman K, Karashchuk G, Lombardo K, Yang D, **Resnick MB**. Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon gamma pathway. *Mod Pathol*. 2017 Jan;30(1):123-133. doi: 10.1038/modpathol.2016.170. Epub 2016 Sep 30. PMID: 27687006.
121. Hui Y, Chen S, Lombardo K, **Resnick MB**, Mangray S, Matoso A. ALOX15 immunohistochemistry aids in the diagnosis of eosinophilic esophagitis on pauci-eosinophilic biopsies in children. *Pediatr Dev Pathol*. 2017 Sep-Oct;20(5):375-380. doi: 10.1177/1093526617693106. Epub 2017 Feb 9. PMID: 28812459.
122. Hui Y, Quddus MR, Murthy JN, Yang D, Sung CJ, Lu S, Resnick MB, Wang LJ. Human papillomavirus genotyping of incidental malignant and premalignant lesions on hemorrhoidectomy specimens *Am J Surg Pathol*. 2017 Mar;41(3):382-388. doi: 10.1097/PAS.0000000000000809. PMID: 28098569.
123. Yakirevich E, Lu S, Allen D, Mangray S, Fanion JR, Lombardo KA, Safran H, **Resnick MB**. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma. *Hum Pathol*. 2017 Aug;66:126-135. doi: 10.1016/j.humpath.2017.06.009. Epub 2017 Jun 28. PMID: 28666927.
124. Siddique AS, Corney DC, Mangray S, Lombardo KA, Chen S, Marwaha AS, Resnick MB, Herzlinger M, Matoso A. Clinicopathologic and gene expression analysis of initial biopsies from patients with eosinophilic esophagitis refractory to therapy. *Hum Pathol*. 2017 Oct;68:79-86. doi: 10.1016/j.humpath.2017.08.027. Epub 2017 Sep 4. PMID: 28882697.
125. Wang Y, Brodsky AS, Xiong J, Lopresti ML, Yang D, Resnick MB. Stromal clusterin expression predicts therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer. *Clin Breast Cancer*. 2018 Jun;18(3):e373-e379. doi: 10.1016/j.clbc.2017.08.007. Epub 2017 Aug 19. PMID: 28890185.
126. Blakely AM, Matoso A, Patil PA, Taliano R, Machan JT, Miner TJ, Lombardo KA, Resnick MB, Wang LJ. Role of immune microenvironment in gastrointestinal stromal tumors. *Histopathology*. 2018 Feb;72(3):405-413. doi: 10.1111/his.13382. Epub 2017 Nov 21. PMID: 28871595.
127. Hui Y, Wang Y, Nam G, Fanion J, Sturtevant A, Lombardo KA, **Resnick MB**. Differentiating breast carcinoma with signet-ring features from gastrointestinal signet-ring carcinoma: assessment of immunohistochemical markers. *Hum Pathol*. 2018 Jul;77:11-19. doi: 10.1016/j.humpath.2018.01.002. Epub 2018 Jan 6. PMID: 29317235.
128. Lu S, Herzlinger M, Cao W, Noble L, Yang D, Shapiro J, Kurtis J, LeLeiko N, Resnick M. Utility of 15(S)-HETE as a serological marker for eosinophilic esophagitis. *Sci Rep* 2018 Sep 28;8(1):14498. doi: 10.1038/s41598-018-32944-8. PMID: 30266946.

## **PUBLICATIONS(continued)**

129. Punsoni M, Friedman JH, Resnick M, Donahue JE, Yang DF, Stopa EG. Enteric pathologic manifestations of alpha-synucleinopathies. *Appl Immunohistochem Mol Morphol*. 2019 Aug;27(7):543-548. doi: 10.1097/PAI.0000000000000613. PMID: 29189256.
130. Hui Y, Lu S, Wang H, **Resnick MB**, Wang Y. Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ – evaluating HER2 in synchronous in-situ and invasive carcinoma. *Histopathology*. 2019 Jan;74(2):358-362. doi: 10.1111/his.13731. Epub 2018 Oct 29. No abstract available. PMID: 30117181.
131. Wang Y, Lu S, Xiong J, Sing K, Hui Y, Zhao C, Brodsky AS, Yang D, Jolly G, Ouseph M, Schorl C, DeLellis RA, **Resnick MB**. ColX $\alpha$ 1 is a stromal component that colocalizes with elastin in the breast tumor extracellular matrix. *J Pathol Clin Res*. 2019 Jan;5(1):40-52. doi: 10.1002/cjp.2.115. Epub 2018 Nov 1. PMID: 30207088.
132. Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, **Resnick MB**. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1 and PD-L1 expression correlate with serrated neoplasia pathway progression. *Hum Pathol*. 2019 Jan;83:115-123. doi: 10.1016/j.humpath.2018.08.020. Epub 2018 Aug 31. PMID: 30172913.
133. Lu S, Wang LJ, Lombardo K, Kwak Y, Kim WH, **Resnick MB**. Expression of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophanyl-tRNA synthetase (WARS) in gastric cancer molecular subtypes. *Appl Immunohistochem Mol Morphol*. 2019 Apr 24. doi: 10.1097/PAI.0000000000000761. [Epub ahead of print]. PMID: 31033497.
134. Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, **Resnick MB**, Moss SF. Retrospective analysis confirms tetracycline quadruple as best *Helicobacter pylori* regimen in the USA. *Dig Dis Sci*. 2019 Oct;64(10):2893-2898. doi: 10.1007/s10620-019-05694-4. Epub 2019 Jun 11. PMID: 31187323.
135. Zhao CL, Singh K, Brodsky AS, Lu S, Graves TA, Fenton MA, Yang D, Sturtevant A, **Resnick MB**, Wang Y. Stromal ColX $\alpha$ 1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. *BMC Cancer*. 2019 Nov 1;19(1):1036. doi: 10.1186/s12885-019-6134-y. PMID: 31675929.
136. Ouseph MM, Taber A, Khursid H, Madison R, Aswad BI, **Resnick MB**, Yakirevich E, Ali SM, Patel NR. TKI-resistant *ALK*-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary *ALK* p.I1171N mutations. *Lung Cancer (Auckl)*. 2019 Aug 15;10:81-86. doi: 10.2147/LCTT.S212406. eCollection 2019. PMID: 31616196.
137. Lu S, Yakirevich E, Wang LJ, **Resnick MB**, Wang Y. Cytokeratin-7 negative and GATA binding protein-3 negative breast cancers: Clinicopathologic features and prognostic significance. *BMC Cancer*. 2019 Nov 12;19(1):1085. doi: 10.1186/s12885-019-6295-8. PMID: 31718619.

## **PUBLICATIONS(continued)**

138. Alpert L, Al-Sabti R, Graham RP, Pai RK, Gonzalez RS, Zhang X, Smith V, Wang HL, Westbrook L, Goldblum JR, Bakhshwin A, Shetty S, Klimstra DS, Shia J, Askan G, Robert ME, Thomas C, Frankel WL, Alsomali M, Hagen C, Mostafa ME, Feely MM, Assarzagdegan N, Misdraji J, Shih AR, Agostini-Vulaj D, Meis JM, Tang S, Chatterjee D, Kang LI, Hart J, Lee SM, Smith T, Yantiss RK, Hissong EM, Gao ZH, Wu J, **Resnick MB**, Wu EY, Pai RK, Zhao L, Doyle LA, Chopra S, Panarelli NC, Hu S, Longacre TA, Raghavan SS, Lauwers GY, Ghayouri M, Cooper HS, Nagarathinam R, Bellizzi AM, Kakar S, Hosseini M, Rong J, Greenon JK, Lamps LW, Dong Z, Bronner MP. Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. *Mod Pathol*. 2020 Jul;33(7):1410-1419. doi: 10.1038/s41379-020-0492-5. Epub 2020 Feb 12. PMID: 32051556
139. Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, Chung C, Elliott H, Glass B, Pethia K, Carrasco-Zevallos O, Shukla C, Khettry U, Najarian R, Taliano R, Subramanian GM, Myers RP, Wapinski I, Khosla A, **Resnick M**, Montalto MC, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Okanoue T, Romero-Gomez M, Goodman Z, Loomba R, Beck AH, Younossi ZM. A **Machine Learning** Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. *Hepatology*. 2021 Jul;74(1):133-147. doi: 10.1002/hep.31750. Epub 2021 Jun 24. PMID: 33570776
140. Baumgartner JM, Srivastava A, Melnitchouk N, Drage MG, Huber AR, Gonzalez RS, Bell P, Wu E, **Resnick M**, Turaga K, Poli E, Esquivel J, Deneve J, Kelly KJ, Veerapong J, Lowy AM. A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. *Ann Surg Oncol*. 2021 Aug;28(8):4685-4694. doi: 10.1245/s10434-020-09499-y. Epub 2021 Jan 7.
141. Loomba R, Nouredin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, **Resnick M**, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhatab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhoury N; ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. *Hepatology*. 2021 Feb;73(2):625-643. doi: 10.1002/hep.31622
142. Diao JA, Wang JK, Chui WF, Mountain V, Gullapally SC, Srinivasan R, Mitchell RN, Glass B, Hoffman S, Rao SK, Maheshwari C, Lahiri A, Prakash A, McLoughlin R, Kerner JK, **Resnick MB**, Montalto MC, Khosla A, Wapinski IN, Beck AH, Elliott HL, Taylor-Weiner A. Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. *Nat Commun*. 2021 Mar 12;12(1):1613. doi: 10.1038/s41467-021-21896-9.
143. Bosch J, Chung C, Carrasco-Zevallos O, Harrison SA, Abdelmalek MF et al. A machine learning approach to liver histological evaluations predicts clinical significant portal hypertension in NASH cirrhosis. *Hepatology* 2021 (accepted for publication)
144. Hu S, Alpert L, Cates JM, Gonzalez RS, Rae GIST Stratification Group. Gastrointestinal tumors arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. *Modern Pathology* 2021 (accepted for publication)

## **PUBLICATIONS(continued)**

145. Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised phase 3 trial. *Lancet Oncology* 2022 (accepted for publication)

## **REVIEWS, EDITORIALS & LETTERS**

1. **Resnick MB**, Weller PF. Mechanisms of eosinophil recruitment. *Am J Respir Cell Mol Biol.* 1993 Apr;8(4):349-55. Review. PMID: 8476627.
2. Sabo E, **Resnick MB**. Letter: Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. *Clin Cancer Res* 2001; 7:3307.
3. Yakirevich E. **Resnick MB**. Editorial: Regulatory T-lymphocytes: pivotal components of the host antitumor response. *J Clin Oncol.* 2007 Jun 20;25(18):2506-8. PMID: 17577026.
4. LeGolvan MP, **Resnick MB** Pathobiology of colorectal cancer hepatic metastasis with an emphasis on prognostic factors. *J Surg Oncol.* 2010 Dec 15;102(8):898-908. doi: 10.1002/jso.21817. Review. PMID: 21165991.
5. Matoso A, **Resnick MB**, Wang LJ. Letter: Comparison of two monoclonal TTF-1 antibodies. *Appl Immunohistochem Mol Morphol.* 2011 Jul;19(4):384. doi: 10.1097/PAI.0b013e31820d12bd. PMID: 21325941.
6. LeGolvan MP, Taliano RJ, **Resnick MB**. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. *Hum Pathol.* 2012 Aug;43(8):1157-68. doi: 10.1016/j.humpath.2012.03.003. Epub 2012 Jun 1. Review. PMID: 22658275.
7. Taliano RJ, LeGolvan M, **Resnick MB**. Immunohistochemistry of colorectal carcinoma: current practice and evolving applications. *Hum Pathol.* 2013 Feb;44(2):151-63. doi: 10.1016/j.humpath.2012.04.017. Epub 2012 Aug 29. Review. PMID: 22939578.
8. Yakirevich E, **Resnick MB**. Pathology of gastric cancer and its precursors. *Gastroenterol Clin North Am.* 2013 Jun;42(2):261-84. doi: 10.1016/j.gtc.2013.01.004. Epub 2013 Mar 1. Review. PMID: 23639640.
9. Matoso A, **Resnick MB**. Letter: Immunohistochemical analysis of eosinophilic esophagitis. *Clin Gastroenterol Hepatol.* 2015 Jun;13(6):1209-10. doi: 10.1016/j.cgh.2014.12.024. Epub 2015 Jan 3. PMID: 25562797.
10. **Resnick MB**. Guest editor and editorial: Imaging advances and applications in medical diagnostics and discovery. 2015; 95/4 *Lab Invest*.
11. Mangray S, Breese V, Jackson CL, Lombardo K, Taliano R, **Resnick M**, Yakirevich E. Application of BRAF V600E mutation analysis for the diagnosis of metanephric adenofibroma *Am J Surg Pathol.* 2015 Sep;39(9):1301-4. doi: 10.1097/PAS.0000000000000501. No abstract available. PMID: 26274032.

## **REVIEWS, EDITORIALS & LETTERS(continued)**

12. **Resnick MB**, Perez K. Advances in the molecular profiling of tumor tissue. *R I Med J* (2013). 2015 Oct 1;98(10):15. No abstract available. PMID: 26422539.
13. Lepe M, O'Connell D, Lombardo KA, Herzlinger M, Mangray S, **Resnick MB**, Matoso A. The inflammatory milieu of eosinophilic esophagitis: a contemporary review with emphasis in putative immunohistochemistry and serologic markers. *Appl Immunohistochem Mol Morphol*. 2018 Aug;26(7):435-444. doi: 10.1097/PAI.0000000000000450. Review. PMID: 27801733.
14. Wang Y, Hui Y, **Resnick MB**. In reply to Lambien et al: 'HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry?' *Histopathology*. 2019 Mar;74(4):666. doi: 10.1111/his.13792. Epub 2019 Jan 15. PMID: 30447011.

## **CHAPTERS IN BOOKS**

1. Frable W, **Resnick MB**, DeLellis R. Molecular Pathology. In: Principles and Practice of Surgical Pathology and Cytopathology, 4<sup>th</sup> ed., 2006.
2. Beck AH, **Resnick MB**, Drumea KC, Sabo E. Quantitative Image Analysis for the Classification of Epithelial Neoplasia. In: Image Analysis in Medical Microscopy and Pathology. Transworld Research Network. Managing Editor: Dr. S.G.Pandalai, 2007.
3. Chatterjee D, Sabo E, **Resnick, MB**, Yeung KC, and Chin YE. The RKIP and STAT3 axis in cancer chemotherapy: opposites attract. In Sensitization of Cancer Cells for Chemo/Immuno/Radiotherapy. Bonavida B. ed. Humana Press, pp 159-174, 2007.
4. Meitner PA, **Resnick MB**. LCM assisted biomarker discovery from archival neoplastic gastrointestinal tissues. *Methods Mol Biol*. 2011;755:165-80. doi: 10.1007/978-1-61779163-5\_13. PMID: 21761302.
5. Yakirevich E, Matoso A, Morris D, **Resnick MB**. Steroid Receptors in Renal Cell Carcinoma. In Tech d.oo. Editor Robert Amato, 2012.

## **PUBLICATIONS, CASE REPORTS**

1. **Resnick MB**, Jacobs DO, Brodsky GL. Multifocal adenocarcinoma in situ with underlying carcinoid tumor of the gallbladder. *Arch Pathol Lab Med*. 1994 Sep;118(9):933-4. PMID: 8080366.
2. **Resnick MB**, Donovan M. Intra-abdominal desmoplastic round cell tumor with extensive extra-abdominal involvement. *Pediatr Pathol Lab Med*. 1995 Sep-Oct;15(5):797-803. PMID: 8597865.
3. Cohen M, Sova Y, Grunwald I, **Resnick M**, Stein A. A rare simultaneous presentation of testicular mixed germ cell tumor and contralateral testicular torsion. *Urology* (online) 2000 Apr;55(4):590. PMID: 10754182.

## **PUBLICATIONS, CASE REPORTS(continued)**

4. Hazzan D, Reissmann D, Halak M, **Resnick MB**, Lotem M, Shiloni E. Primary rectal malignant melanoma: report of two cases. *Tech Coloproctol*. 2001 Apr;5(1):51-4. PMID: 11793262.
5. Yakirevich E, Sova Y, Drumea K, Bergman I, Quitt M, **Resnick MB**. Peripheral lymphadenopathy as the initial manifestation of pericardial mesothelioma: a case report. *Int J Surg Pathol*. 2004 Oct;12(4):403-5. PMID: 15494868.
6. Hyatt P, **Resnick M**, Habr F, Baffy G. Brunner's gland hamartoma. *Clin Gastroenterol Hepatol* 2006 Jul;4(7):A26. PMID: 16630774.
7. Alduaij AA, **Resnick MB**, Kawata M, Pricolo VE. Metastatic malignant melanoma presenting as an appendiceal mucocele. *J Oncol*. 2011;2011:546570. doi: 10.1155/2011/546570. Epub 2011 Mar 30. PMID: 21547210.
9. **Resnick M**, Pricolo V, Chen S. Carcinoid tumor of the ileoanal pouch in a patient with ulcerative colitis. *R I Med J* (2013). 2013 Jan 4;96(1):30-1. PMID: 23638456.
10. Fyock C, Gaitanis M, Gao J, **Resnick M**, Shah S. Gastrointestinal CMV in an elderly, immunocompetent patient. *R I Med J* (2013). 2014 Jun 2;97(6):53-6. PMID: 24905377.
11. Taliano RJ, Godfrey M, Garland JM, Taylor LE, Wood S, **Resnick MB**. The great mimicker strikes again: an unusual case of syphilitic hepatitis with marked sinusoidal histiocytic infiltrate. *AJSP: Reviews & Reports* 2017; 22 (3), 143-145.

## **PUBLICATIONS, THESIS**

Hematological and Bacteriological Aspects of Murine Leprosy. Research advisers: Herve Bercovier, D.V.M. and Louis Levy, M.D., Ph.D., 1989.

## **INVITED PRESENTATIONS**

1. "Update on Thyroid Tumor Pathology". Israel Society of Pathology. Tel-Aviv University, April 1999.
2. "Apoptosis, proliferation and Fas/Fas-ligand expression in medullary carcinoma of the breast". Department of Pathology, University of Massachusetts School of Medicine, March 2001.
3. "Mechanisms of cytotoxicity in medullary carcinoma of the breast". Department of Pathology, University of Chicago School of Medicine, March 2001.
4. "Cytotoxic mechanisms in tumor immunology". Department of Pathology, Rhode Island Hospital, Providence, October 2001.

## **INVITED PRESENTATIONS(continued)**

5. "Apoptosis and cytotoxic mechanisms in testicular seminoma and medullary carcinoma". Department of Pathology, University of Vermont School of Medicine, October 2001.
6. "Apoptosis, proliferation and Fas/Fas-ligand expression in medullary carcinoma of the breast". Department of Pathology, Children's Hospital, Boston MA, October 2001.
7. "EGF-R and related protein expression in GI malignancies". GI Committee Liaison Meeting. Radiation Tumor Oncology Group, Washington DC, June 2004.
8. "Global analysis of the human gastric epithelial transcriptome altered by H. pylori eradication in vivo. Workshop in Honor of Dr. James Madara, Chicago, October 2006.
9. "Identification of novel gastric tumor biomarkers using LCM on formalin fixed tissues" Gene Expression in Tumors: Discover and Diagnostics. Department of Pathology, Children's Hospital, Boston, December 2006.
10. "Update in Gastric Pathology" Division of Gastroenterology, The Warren Alpert Medical School of Brown University, Providence, RI, November 2007.
11. "Biomarkers in Barrett's esophagus associated high grade dysplasia" Laser Capture Microdissection Workshop, Boston MA, October 2009.
12. "Update Pathology of Inflammatory Bowel disease" Colorectal Symposium: What's New in Inflammatory Bowel Disease. Providence, RI, November 2010.
13. "Challenges in the Field of Barrett's Esophagus and the Need for Biomarkers of Neoplasia" Department of Pathology and Laboratory Medicine, Providence RI, January 2011.
14. "Controversies and Challenges in the Pathology of Barrett's Esophagus" Histopathology, Faculty of Medicine Imperial College London England, May 2011.
15. Barrett's Esophagus: Update 2011. Department of Pathology Columbia University NY, October 2011.
16. "Helicobacter Pylori: Mechanisms of Microbial Pathogenesis" Hebrew University, Jerusalem, Israel, January 2012.
17. "Chronic Gastritis: Practical Aspects" Tel Hashomer Hospital, Tel-Aviv, Israel, July 2014.
18. "Chronic Gastritis: Practical Aspects" Rambam Medical Center, Technion University Israel, July 2014.
19. "Ideal Workup of Cancers of Unknown Primary", Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, December 2014
20. "Contemporary Cases in GI Pathology" Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, December 2014.

## **INVITED PRESENTATIONS(continued)**

21. Harvard CME Course: Gastrointestinal, Liver and Pancreatic Pathology: Hitting a moving target: Workup of GI tumors of unknown primary, Boston MA, May 2015.
22. Harvard CME Course: Gastrointestinal, Liver and Pancreatic Pathology: Practical Aspects Molecular Pathology of Colorectal Cancer, Boston MA, May 2016.
23. “Medullary Carcinoma of the Colon: The Ultimate MSI Tumor” Rambam Medical Center, Technion University Israel, June 2016.
24. Annual Midwestern Conference Update in Surgical Pathology, “Chronic Gastritis a Practical Approach”, Milwaukee WI, October, 2016.
25. Annual Midwestern Conference Update in Surgical Pathology, “Update on the Molecular Pathology of Colorectal Cancer” Milwaukee WI, October, 2016.
26. Harvard CME Course: Gastrointestinal, Liver and Pancreatic Pathology: Practical Aspects Molecular Pathology of Colorectal Cancer, Boston MA, May 2017.
27. Harvard CME Course: Gastrointestinal, Liver and Pancreatic Pathology: Practical Aspects Molecular Pathology of Colorectal Cancer, Boston MA, May 2018.
28. Arkadi Rywlin Slide Seminar, Split Croatia, May 2018.
29. Surgical Pathology Update, Brigham and Women’s Hospital, Artificial Intelligence and NASH, February 2021

## **PATENTS**

1. Brodsky A, Wang Y, **Resnick, M.** Collagens as Markers for Breast Cancer Treatment. US Patent Application: 15/187,279.
2. Resnick M. Differential Expression of Protein Markers for the Diagnosis and Treatment of Eosinophilic Esophagitis 14/435,059.

## **GRANT SUPPORT**

1. COBRE Center for Cancer Research Development #1P30GM110759-01A1  
(previously awarded under #P20RR017695 and #P20GM103421)  
Molecular Pathology Core  
National Institutes of Health/National Institute of General Medical Sciences  
(previous award National Center for Research Resources)  
09/30/02–04/30/20  
Role: Co-Investigator/Director, Molecular Pathology Core
2. Describing Genomic Heterogeneity in Cancer  
Rhode Island Commerce Corporation  
Medley Genomics/HG Diagnostics  
05/01/17-04/30/18  
Role: Principal Investigator



**GRANT SUPPORT(continued)**

3. The Mevalonate Pathway Regulates Drug Resistance in Colorectal Cancer  
COBRE Center for Cancer Research Development Pilot Award #1P30GM110759-01A1  
National Institutes of Health  
10/1/15-09/30/17  
Role: Mentor to Dr. Alexander Brodsky (PI)
4. A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2  
Overexpressing Esophageal Adenocarcinoma  
#RTOG-1010  
National Institutes of Health NCI CTROC BIQSFP  
Radiation Therapy Oncology Group  
01/01/10-11/30/15  
Role: Co-Principal Investigator
5. Microbiomes in Human Pancreatic Cancer #R01CA166150  
National Institutes of Health  
07/01/13-03/31/16  
Role: Co-Investigator
6. Single Agent Adjuvant Aflibercept for Patients with Resected or Ablated Metastatic  
Colorectal Cancer: A Randomized Phase II Study #BrUOG-261  
SANOFI  
12/01/12-11/31/13  
Role: Co-Investigator
7. Evaluation of Guanylyl Cyclase C, Shc Proteins and MSI for Colon Cancer Staging and  
Prognosis #DIAG-09/001-R  
Diagnocure  
08/01/09-07/31/10  
Role: Principal Investigator
8. Biomarker for Hepatocellular Carcinoma #5 R01 CA123544-02  
National Institutes of Health  
12/01/07-11/30/12  
Role: Co-Investigator
9. Analysis of the Prognostic and Therapeutic Utility of Phosphorylated EGF-R in Human  
Pancreatic Cancer  
  
#CA21661  
Radiation Tumor Oncology Group (seed grant)  
01/01/04-12/31/04  
Role: Principal Investigator
10. Molecular Epidemiology of Colorectal Cancer #R01 CA81488-01  
National Cancer Institute  
01/01/01 – 01/01/05  
Role: Adviser/Co-Investigator

## **GRANT SUPPORT(continued)**

11. Heterogeneity in Tumor Angiogenesis  
Israel Cancer Research Fund  
03/01/00 – 03/01/02  
Role: Co-Principal Investigator with Dr. Andrew Levy
12. Expression of Fas/Fas-ligand in the normal and neoplastic breast  
Israel Cancer Society  
05/01/00 – 05/01/01  
Role: Principal Investigator
13. Expression of Neuroleukin-like sperm antigen during spermatogenesis  
Ministry of Health/Technion, Carmel, Israel  
01/01/99 – 01/01/00  
Role: Co-Investigator
14. Collagenase type I and TIMP-I gene expression and activity in neoplastic and non-neoplastic human thyroid cells.  
Israel Cancer Society  
05/01/98 – 05/01/94  
Role: Co-Investigator
15. Characterization of Targets for the VHL Tumor Suppressor in Renal Carcinoma  
Israel Cancer Research Fund  
03/01/97 – 03/01/99  
Role: Co-Investigator

## **UNIVERSITY TEACHING ROLES**

- 2003-2009 Course Leader, Applied Pathology 611, The Warren Alpert Medical School of Brown University
- 2003-2009 GI Pathology, Pathology of Systems, The Warren Alpert Medical School of Brown University
- 2003-2010 Mentor, Summer Research Assistantships, The Warren Alpert Medical School of Brown University
- 2005-2009 Lecturer, Molecular Mechanisms of Disease, The Warren Alpert Medical School of Brown University

## **HOSPITAL TEACHING ROLES**

- 2003-2019 Director, Gastrointestinal Pathology Fellowship Program, Rhode Island Hospital
- 2003-2009 Director Surgical Pathology Fellowship Program, Rhode Island Hospital
- 2002-2019 Pathology Residents, Rhode Island Hospital, approx. 3 one-hour teaching sessions per year, 12 students
- 2002-2007 Gastrointestinal (Medicine) Fellows, Rhode Island Hospital, one-month tutorial per fellow, per year (2-3 fellows per year)
- 2002-2019 Pathology Residents and Fellows, Rhode Island Hospital, approximately 250 hours of direct microscopy training sessions each year.

### **INTERDEPARTMENTAL CONFERENCES**

- 2002-2019 GI and Liver Biopsy Conference, Rhode Island Hospital, one-hour per week  
2002-2019 GI Tumor Board, Rhode Island Hospital, one-hour every other week  
2002-2010 Oncology Tumor Board, Rhode Island Hospital, one-hour per month

### **OTHER TEACHING ROLES**

- 1999-2002 Director Pathology for Laboratory Science Course, Technion, Israel  
1996-2002 Pathology of Systems, Technion Medical School, Israel  
1994 Gastrointestinal Pathology, Harvard Medical School, Boston, MA  
1992-1994 Gastrointestinal Pathophysiology, Harvard-MIT program in Health Sciences and Technology, Boston, MA

### **GI and SURGICAL PATHOLOGY FELLOW TRAINEES**

- 2003-2004 Peter Wu MD  
2004-2005 JiYi Wang MD, Chen Xu MD, Yaoxian Ding MD  
2005-2006 Adam Carter MD, James Carlsten MD  
2006-2007 Gerald Bailey MD/PhD, John Gao MD/PhD  
2007-2008 Mark LeGolvan MD, Samantha Easley MD  
2008-2009 Preeti Sharma MD, Tara Williams MD  
2009-2010 Katherine Sciandra MD, Brody Winn MD  
2010-2011 Ajay Patel MD  
2011-2012 Webiao Cao MD/PhD, Nick Shillingford MD  
2012-2013 Andres Matoso MD, Danisha Allen MD  
2013-2014 Shaolei Lu MD/PhD, Anthony Snow MD  
2014-2015 Elizabeth Kalife MD, Kenneth Friedman MD  
2015-2016 Stephanie Wood MD  
2016-2017 Lisa Laskowicz MD  
2017-2018 Gabriel Acosta-Gonzalez MD  
2018-2019 Osman Yilmaz MD

### **PhD COMMITTEE (Brown University)**

- 2008-2010 Graham Poage (Carmen Marsit PhD mentor)  
2011-2013 Waihong Chung (Jack Wands MD mentor)  
2011-2013 Jennifer Joukhadar (Karl Kelsey PhD mentor)

### **COMPLETED THESES - GRADUATE STUDENTS**

- 2003 Miriam Gibra, MD. Thesis, Histomorphometric Features of Complexity vs Histological Grade in Transitional Cell Carcinoma of the Bladder  
2003 Doron Sudarski, MD. Thesis, Histomorphometric Nuclear Features with an Emphasis on Nuclear Fractal Geometry as Possible Prognostic Factors in Renal Cell Carcinoma

**COMPLETED THESES - GRADUATE STUDENTS(continued)**

- 2002 Ylena Kartivashvilli, MSc. Thesis, The Role of Neuropilin-2 in Pancreatic Neuroendocrine Pathophysiology
- 2001 Oved Yehezkel, MD. Thesis-Metallinoproteinase Activity in Thyroid Neoplasms
- 2001 Nimrod Goldschmidt, MD. Basic Science Thesis, Mast Cell and Neural Density in Vulvar Vestibulitis
- 2001 Oleg Lefel, MD. Basic Sciences Thesis, Activated status of tumor infiltrating lymphocytes and apoptosis in testicular seminoma.
- 2000 Shira Kleinhauz, MD. Thesis, Expression of Angiogenic Factors and Their Receptors in Renal Cell Carcinoma (with Dr Nitzan Resnick)
- 2000 Albina Boltenko, MD. Thesis, Vascular Complexity as a Novel Prognostic Factor in Renal Cell Carcinoma
- 1996 Leonid Zeitlin, MD. Basic Science Thesis-Phenotype of Extracellular Matrix in Neonatal Liver Disease (with Dr. Shimon Reif Sourasky Medical Center)